Sanjivani Paranteral Limited: Q3 FY26 Sees Strong Growth Driven by Strategic Diversification

Sanjivani Paranteral Limited, a WHO GMP-certified pharmaceutical manufacturer with over 25 years of experience, has reported a robust performance for the third quarter of fiscal year 2026. The company achieved a consolidated revenue from operations of INR 22.06 crores, marking a significant year-on-year growth of 27.2%. This impressive top-line expansion was complemented by a substantial increase in profit after tax (PAT), which surged by 46.2% to INR 2.78 crores. The management highlighted Q3 FY26 as a pivotal quarter, signifying a successful transition from a single-engine business model to a diversified, multi-vertical growth platform, with new strategic ventures beginning to contribute meaningfully to the company's consolidated performance.

The company's strategic shift towards diversification is clearly yielding results. The Pune infusion facility, established through a joint venture in IV fluids in India, has started contributing to consolidated revenues for the first time. Simultaneously, the Prague-based nutraceutical venture is gaining significant commercial traction, particularly in European markets, indicating successful penetration into new geographies and product segments. While standalone injectable revenues saw a slight decline of 9.7% year-on-year, the overall growth was propelled by strong performance in other segments and the initial contributions from these new ventures. The management emphasized that these strategic investments over the past few years are crucial for diversifying both their manufacturing base and revenue streams, setting the stage for sustained growth.

Strategic Initiatives and Future Outlook

Sanjivani Paranteral Limited's growth strategy is built on several key pillars, including expanding its product portfolio, forging strategic partnerships, and diversifying into new geographies and therapeutic areas. The company's management articulated a clear vision for the future, projecting the core base business to achieve approximately INR 90 crores in top-line revenue for FY27. The SPL Infusion Private Limited (Pune plant) is expected to contribute an additional INR 60-65 crores in FY27, with a target of 40-50% capacity utilization. At peak capacity, the Pune facility is anticipated to generate over INR 120-130 crores in revenue with EBITDA margins ranging from 19-20%. This measured ramp-up strategy for the Pune plant involves a focus on securing approvals for 20-23 specialized products, which are expected to fetch better margins and pricing.

Operational Excellence and Regulatory Compliance

Operational excellence and stringent regulatory compliance remain central to Sanjivani's strategy. The company has successfully addressed past logistical challenges in African markets by establishing multiple shipping routes, ensuring supply continuity. A significant green flag for the company is its full compliance with the revised Schedule M by the FDA. Management proudly reported that all their plants meet these updated standards, a notable achievement given that only an estimated 20-30% of plants in India are expected to comply. This proactive approach not only mitigates regulatory risks but also positions Sanjivani as a reliable and high-quality manufacturer in a competitive landscape.

Shareholding and Capital Allocation

Regarding capital allocation, the company plans a capex of INR 4-4.5 crores for FY27, primarily for upgrading machines and software in its base business plants in Mumbai and Dehradun. This disciplined capital allocation is aligned with maintaining operational efficiency and quality. Furthermore, the promoters have consistently increased their shareholding in the company year-on-year, including the conversion of warrants. This continuous insider buying signals strong confidence in the company's long-term prospects and strategic direction, reinforcing investor trust.

Sanjivani Paranteral Limited's Q3 FY26 performance underscores its strategic clarity and disciplined execution. The company is effectively leveraging its new ventures and robust compliance framework to drive growth and diversify its revenue streams. With a clear roadmap for capacity utilization, product expansion, and financial targets, Sanjivani is well-positioned for sustained growth in the evolving pharmaceutical market.